1. St. John’s wort: Most pharmacists are familiar with this herbal supplement and its (unapproved) use for depression. Some may not be aware that it can be a component in “detox” supplements and may be used by some to self-treat alcohol dependence. There have been some scientific studies investigating the use of St. John’s wort to treat alcohol addiction in rat models that showed some promise. The use of St. John’s wort reduced alcohol intake in rats, but there’s scant evidence that St. John’s wort can have a similar impact in human subjects.2,3 Currently, the known risks of taking St. John’s wort far outweigh any potential clinical benefit.
2. Ashwagandha: This herbal supplement is used in traditional Ayurvedic medicine and has been used by some to overcome alcohol withdrawal or cravings. Many claim that it has anxiolytic effects that helps prevent alcohol cravings. Rat studies showed that Ashwagandha lowered anxiety associated with alcohol withdrawal, but its impact on seizure threshold hasn’t been thoroughly established.4,5 There’s currently no convincing evidence in human subjects that supports its use in treating alcohol dependency.
3. Kudzu: Kudzu is often advertised as a way for drinkers to cut back on alcohol. It’s thought to act as an “aversion” agent, inhibiting the clearance of acetaldehyde (a toxic metabolic byproduct of alcohol), which may decrease alcohol cravings. This is similar to how the approved drug Antabuse (disulfiram) works in the body.6 Modest reductions in alcohol intake were noted in a single study of young human subjects taking kudzu extract.7 Other studies didn’t mirror these results in humans subjects.8 Kudzu hasn’t yet shown a clear benefit to drinkers trying to reduce alcohol consumption.
As with many other OTC herbal supplements, there’s little convincing evidence that the aforementioned supplements are clinically effective treatments of alcohol dependency. There have been some scientific studies conducted, but a majority involve animal models and show modest findings that rarely translate into conclusive human trials. The primary danger of these supplements in those with alcohol dependency is not necessarily knowing the drug–drug interaction potential or side effects. The real danger may be the possible delay in seeking professional help for the dependence. If asked about herbal treatments for a drinking problem, it is advisable to recommend speaking with a professional rather than self-treatment with over-the-counter supplements.
1. Dearing RL, Stuewig J, Tangney JP. On the importance of distinguishing shame from guilt: Relations to problematic alcohol and drug use. Addict Behav. 2005;30(7):1392-1404.
2. Rezvani AH, Overstreet D, Yang Y, Clark E. Attenuation of alcohol intake by extract of Hypericum perforatum (St John’s wort) in two different strains of alcohol-preferring rats. Alcohol and Alcoholism. 1999;34(5):699-705.
3. De Vry J, Maurel S, Schreiber R, De Beun R, Jentzsch K. Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. European Neuropsychopharmacology. 1999;9(6):461-468.
4. Ruby B, Benson MK, Kumar EP, Sudha S, Wilking JE. Evaluation of Ashwagandha in alcohol withdrawal syndrome. Asian Pacific Journal of Tropical Disease. 2012;2:S856-S860.
5. Mohan L, Rao U, Gopalakrishna H, Nair V. Evaluation of the anxiolytic activity of NR-ANX-C (a polyherbal formulation) in ethanol withdrawal-induced anxiety behavior in rats. Evid Based Complement Alternat Med. 2010;2011. pii: 327160. doi: 10.1155/2011/327160.
6. McGregor NR. Pueraria lobata (Kudzu root) hangover remedies and acetaldehyde-associated neoplasm risk. Alcohol. 2007;41(7):469-478.
7. Lukas SE, Penetar D, Su Z, et al. A standardized kudzu extract (NPI-031) reduces alcohol consumption in nontreatment-seeking male heavy drinkers. Psychopharmacology. 2013;226(1):65-73. doi: 10.1007/s00213-012-2884-9.
8. Shebek J, Rindone JP. A pilot study exploring the effect of kudzu root on the drinking habits of patients with chronic alcoholism. J Altern Complement Med. 2000;6(1):45-48.
Erik Hefti, PharmD, MS, PhD
Erik Hefti holds a PharmD as well as a Master's and PhD degrees in pharmaceutical science from the University at Buffalo. His research focuses on pediatric pharmacogenomic factors impacting cardiovascular toxicity following cancer chemotherapy and genetic testing utilization to improve healthcare outcomes. His clinical focus involves optimizing pharmacotherapy in patients with genetic disorders. He is the program director and assistant professor of pharmaceutical sciences at Harrisburg University in Harrisburg, PA.